Anti-Diabetes Drugs - EU-27

EU-27

The Anti-Diabetes Drugs market in EU-27 is expected to witness a significant growth in revenue, reaching a projected value of US$9.10bn by 2024.
This market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 6.94%, leading to a market volume of US$12.73bn by 2029.
In comparison to other countries, United States is projected to generate the highest revenue of US$37,840.00m in 2024.
In EU-27, Germany leads the market for anti-diabetes drugs with a strong emphasis on research and development.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in EU-27 has been experiencing a steady growth in recent years.

Customer preferences: The increasing prevalence of diabetes in the EU-27 region has led to a rise in demand for anti-diabetes drugs. Patients are seeking drugs that are effective, have minimal side effects, and are affordable. Additionally, there is a growing preference for drugs that can be administered orally rather than through injections.

Trends in the market: The EU-27 region has seen an increase in the use of newer anti-diabetes drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors. These drugs have shown promising results in managing blood sugar levels and have fewer side effects than traditional drugs such as metformin. There has also been a shift towards personalized medicine, with doctors prescribing drugs based on the patient's individual needs and medical history.

Local special circumstances: The EU-27 region consists of diverse countries with varying healthcare systems and regulations. This has resulted in differences in the availability and pricing of anti-diabetes drugs across the region. For example, in some countries, newer drugs may be more widely available and affordable, while in others, they may be restricted due to cost or regulatory issues.

Underlying macroeconomic factors: The aging population in the EU-27 region has contributed to the rise in diabetes cases and subsequently, the demand for anti-diabetes drugs. Additionally, the increasing prevalence of obesity and sedentary lifestyles has also led to a higher incidence of diabetes. The economic burden of diabetes on healthcare systems has also led to a focus on preventive measures and the development of more effective drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.